Dr. Dawn Bravo is a research scientist at Stanford University School of Medicine. She won the 2006 NIH Ruth L. Kirschenstein National Research Service Award and her postdoctoral studies at the Thoracic Oncology Laboratory were under the auspices of another NIH research service award. Dr. Bravo is very experienced in NIH grant submissions and the management and successful completion of NIH-funded studies.
Our team at Dale Biotech recognizes the need for the best scientific minds to come together to tackle the current health crisis related to COVID-19.
We are also committed to using our expertise with Rhamnolipids to develop an oral formulation which is not only efficacious but also cost effective. Our experience with Rhamnolipids and our early research with niclosamide, has led us to a unique formulation that has the potential to not only treat early cases of COVID-19 but also could be used for prophylaxis against COVID-19 and other future viral threats.
Please join us , as an investor or as follower, and support our efforts to combat this worldwide pandemic.